Such shocking and terrible news. Please have his family in your thoughts, and consider supporting his family if you have the means.

My secret to being a good doc is working with great nurses and APPs. So a special shout out to the Heme Malignancy nurses that *dominated* our nursing awards! Kim Laino (who’s been w me through it all!), Kira Lynn Voitle, Kathy Kafka, Joyce Herrera - so proud! Rutgers Cancer Institute

📶 We continue to grow! See below for a new BMT & CART faculty/physician position at RWJBarnabas & Rutgers Cancer Institute. Be part of a dynamic & highly collaborative #BloodCancer team, led by Matthew Matasar, MD (cinj.org/patient-care/a…). nejmcareercenter.org/job/775936/att… 1/3

OLYMPIA-3 is a trial-in-progress for patients with newly diagnosed DLBCL evaluating O-CHOP (odronextamab + chop). Spoke with Oncology Learning Network to give the skinny - thrilled to be trying to move #bispecifics to the first line! Regeneron hmpgloballearningnetwork.com/site/onc/confe…

Way to go Dr.Tiger! Women in Lymphoma - [email protected] #risingstar

Proud to share that Rutgers Cancer Institute has successfully treated our 200th patient with #CART therapy. And we’re only getting started, with NJ’s only CAR-T GMP facility and leadership in innovative clinical trials! cinj.org/200th-car-t-ce…

Enjoyed talking with Jennifer Crombie, MD about the present (and future!) of #bispecifics in B-cell lymphoma!

📊 Stay updated on the standards of care for hematologic malignancies and enhance your skills in community-based management. 💉 Gain confidence in tailoring patient-centric treatment plans for optimal outcomes. Join our expert Matthew Matasar, MD 📍 ms.spr.ly/6011WMkdJ #ASH24

Great conversation with Jennifer Crombie, MD about #bispecifics #bsab with a focus on deploying them in community settings!

Exploring the Management of Cytokine Release Syndrome With Jennifer Crombie, MD Dana-Farber Harvard Medical School and Matthew Matasar, MD Rutgers Cancer Institute targetedonc.com/view/exploring…

Hope to see you at #ASH24 - should be a great session alongside superstars 💫 Chan Cheah @UjjaniC Nisha Joseph, MD and Luciano J Costa 💫

👏👏 Kudos to adult & pediatric Chiefs Matthew Matasar, MD & Peter Cole for GREAT achievement at the ASH #hematology symposium this year (6⃣6⃣ at the 6⃣6⃣th #ASH24). 🎉🎉An extra call-out to drjoannarhodes directing the #lymphoma program to nearly 50 lymphoid presentations!

#ASH24 come check out the VR and digital avatars with Encompass - moving education around bispecifics into the future!

Don’t miss Matthew Matasar, MD’s oral presentation today at #ASH24 highlighting innovative findings from the ELM-1 study on the efficacy and safety of odronextamab monotherapy for patients with relapsed/refractory #DLBCL. Learn more about the research here: bit.ly/4eR8T8I

Advances in MCL and FL from #ASH24. With Laurie Sehn of BC Cancer, Tim Fenske of Medical College of Wisconsin, Christina Poh, MD of Fred Hutch Cancer Center & University of Washington, Dr Sunita Nasta of Penn Medicine - Abramson Cancer Center, Tycel Phillips of City of Hope, Matthew Matasar, MD of Rutgers Cancer Institute, and more. #lymsm cancertherapyadvisor.com/indepth/ash-20…

Odronextamab post-CAR: glad to have shared our updated data from #ELM1 with Oncology Learning Network at #ASH24 hmpgloballearningnetwork.com/site/onc/confe…

Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma. #lymsm | Matthew Matasar, MD cancernetwork.com/view/prior-car…